News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cellectricon Announces Cellaxess® ACE Project Grant Winners


9/19/2013 10:07:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Molndal, Sweden – 19 September 2013 – Cellectricon, a leading provider of advanced cell-based screening technologies and services, has announced the two winners of its Cellaxess® ACE project grant, supporting cutting-edge research in cell biology. The grant was awarded for project proposals utilizing Cellectricon’s Cellaxess ACE technology for the delivery of non-genetic material to adherent cells and cultures. The winners not only receive a Cellaxess ACE module and consumables, but will also benefit from Cellectricon’s on-going support and expertise throughout the project’s duration. Cellaxess ACE is a single electrode based electroporation system optimized for the in-situ transfection of all adherent cell types, which offers superior efficiency and cell viability due to minimal cell processing and the low voltages required.

The awards were granted for two categories: Applied Cell-Based Research and Basic Cell-Based Research. Dr Hakim Djaballah, Director of the HTS Core Facility, Memorial Sloan-Kettering Cancer Centre, New York, received the award for Applied Research. His project looks at small molecule delivery in 3D cell models using electroporation, benefiting from Cellectricon’s Cellaxess ACE technology to push the limits of compound delivery to all cells of a 3D spheroid, not just those at the periphery. In such a fast-paced research area, compound uptake in a 3D system has major implications for translational medicine.

Exploring the intracellular delivery of Ca2+ channel peptides using the Cellaxess ACE, Dr Gary Stephens, Director of Pharmacology at the University of Reading School of Pharmacy, received the award for Basic Cell-based Research. The group has recently developed synthetic peptides for decreasing the Ca2+ influx into neurons, which therefore modulates synaptic transmission. Using the Cellaxess ACE to deliver these peptides will be instrumental in examining their modulatory effects in adherent neurons, potentially leading to therapeutic agents in areas such as pharmacoresistant pain.

Dr Johan Pihl, product manager for the Cellaxess ACE, comments: “We were delighted with the response to our Cellaxess Project Grant – with so many highly qualified applications, choosing the winning abstracts was a tough decision. It’s going to be exciting to see how our Cellaxess technology enhances this cutting-edge research.”

Over the course of the research projects, Cellectricon will be publishing the latest developments, and you can either keep up to date via our Newsletter, or connect with us on LinkedIn.

For more information on Cellectricon, or to sign up to our Newsletter visit www.cellectricon.com

About Cellectricon

Cellectricon provides state-of-the-art discovery services and enabling technologies to accelerate drug discovery and cell-based research. Our compound profiling services in excitable cells and native tissue provide researchers with decision-making insight into the science of cytoskeletal disturbances, with an initial focus on chronic pain.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES